Compare ALKS & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKS | TVTX |
|---|---|---|
| Founded | 1987 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2012 | 2013 |
| Metric | ALKS | TVTX |
|---|---|---|
| Price | $38.99 | $44.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $43.43 | $40.62 |
| AVG Volume (30 Days) | 1.7M | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | N/A | N/A |
| Revenue | ★ $1,475,899,000.00 | N/A |
| Revenue This Year | $24.26 | $44.76 |
| Revenue Next Year | $4.47 | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.17 | $13.88 |
| 52 Week High | $38.45 | $48.61 |
| Indicator | ALKS | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.82 | 65.78 |
| Support Level | $27.65 | $26.97 |
| Resistance Level | N/A | $48.61 |
| Average True Range (ATR) | 1.29 | 2.26 |
| MACD | 0.34 | -0.26 |
| Stochastic Oscillator | 87.89 | 53.95 |
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.